• A U.S. health advisory committee is reconsidering its previous position against recommending mRNA vaccines.
• This review comes shortly after the FDA reversed its initial refusal to review Moderna’s mRNA based flu vaccine application.
• The developments directly relate to Moderna’s mRNA vaccine portfolio and potential demand for its products.

For you as an investor following NasdaqGS:MRNA, this is a core business story rather than a side issue. Moderna is primarily focused on mRNA based vaccines and therapeutics, so any change in official guidance on mRNA use, together with the FDA’s willingness to review its flu vaccine application, is closely tied to its commercial opportunity set. These regulatory discussions are central to how broad…